These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Thompson TR; Lal S; Yassa R; Gerstein W Acta Psychiatr Scand; 1988 Dec; 78(6):763-5. PubMed ID: 3223334 [TBL] [Abstract][Full Text] [Related]
7. Relation of graded ocular anterior chamber pigmentation to phenothiazine intake in schizophrenics--quantification procedures. Thaler JS; Curinga R; Kiracofe G Am J Optom Physiol Opt; 1985 Sep; 62(9):600-4. PubMed ID: 4050962 [TBL] [Abstract][Full Text] [Related]
8. Cutaneous and ocular changes associated with the use of chlorpromazine. Wolf ME; Richer S; Berk MA; Mosnaim AD Int J Clin Pharmacol Ther Toxicol; 1993 Aug; 31(8):365-7. PubMed ID: 8225679 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic drug doses in a schizophrenia inpatient unit. Galletly CA Aust N Z J Psychiatry; 1992 Dec; 26(4):574-6. PubMed ID: 1362051 [TBL] [Abstract][Full Text] [Related]
14. Therapy of Phenothiazine-produced skin pigmentation: a preliminary report. Gibbard BA; Lehmann HE Am J Psychiatry; 1966 Sep; 123(3):351-2. PubMed ID: 5917622 [No Abstract] [Full Text] [Related]
15. Physical signs for the General Dental Practitioner. Case 19. Pigmentation disorder. Bain S; Hamburger J Dent Update; 2004 Nov; 31(9):560. PubMed ID: 15612464 [No Abstract] [Full Text] [Related]
16. Antipsychotic medication: clinical guidelines for maintenance therapy. Johnson DA J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281 [TBL] [Abstract][Full Text] [Related]
17. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up. Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924 [TBL] [Abstract][Full Text] [Related]